Surface enhanced laser desorption ionization in melanoma

$0P30FY2001ARNIH

Brigham And Women'S Hospital, Boston MA

Investigators

Linked publications & trials

Paper 28468973 Paper 28219080 Paper 24490023 Paper 24300535 Paper 23912587 Paper 23785046 Paper 23659714 Paper 23419694 Paper 22854780 Paper 22718118 Paper 22661700 Paper 22560445 Paper 22546478 Paper 22441365 Paper 22318381 Paper 22184093 Paper 22120429 Paper 21925467 Paper 21445060 Paper 21410764 Paper 21056730 Paper 21042878 Paper 20972432 Paper 20577213 Paper 20482672 Paper 20460482 Paper 20042675 Paper 20023213 Paper 19889975 Paper 19796236 Paper 19516264 Paper 19489101 Paper 19290804 Paper 19229187 Paper 19172691 Paper 19147830 Paper 18804386 Paper 18794336 Paper 18690246 Paper 18670585 Paper 18647941 Paper 18615110 Paper 18560367 Paper 18480426 Paper 18426917 Paper 18312434 Paper 18202660 Paper 18178870 Paper 18056398 Paper 18045540 Paper 17482714 Paper 17473183 Paper 17334369 Paper 17132831 Paper 17086187 Paper 16951687 Paper 16886055 Paper 16723698 Paper 16691194 Paper 16617337 Paper 16565724 Paper 16547281 Paper 16484986 Paper 16446420 Paper 16417231 Paper 16354178 Paper 16224538 Paper 16141245 Paper 15994950 Paper 15701088 Paper 15606674 Paper 15381720 Paper 15357943 Paper 15319280 Paper 15292489 Paper 15289332 Paper 15191548 Paper 15184268 Paper 15084269 Paper 15070899 Paper 15032599 Paper 14993263 Paper 14523038 Paper 14506741 Paper 14504094 Paper 12900763 Paper 12875969 Paper 12759452 Paper 12393521 Paper 12130499 Paper 11781236 Paper 11696600 Paper 11641609 Paper 11453631 Paper 10751363 Paper 10713722 Paper 10648628

Abstract

The incidence of malignant melanoma is increasing worldwide at rates that have been reported to be between 3 and 7%. In the United States, the incidence of melanoma is rising faster than any other malignancy. The overall goal of this project is to test the feasibility of using of Surface-Enhanced Laser Desorption/Ionization (SELDI) in melanoma biomarker discovery. The ultimate goal of the project is to develop proteomic approaches to the early detection of melanoma which can be utilized for screening. prognostication, selection of therapy, identification of potential targets for immunotherapy and the measurements of responses to therapy. The approach involves making no a priori assumptions regarding the nature of the proteins that may be useful as markers of melanoma but rather provides a high throughput system for analyzing the entire sample, in this project, the blood. The specific aims are as follows: 1. To determine which combination of conditions are most suitable for screening protein peaks in plasma. 2. To perform a preliminary evaluation of 25 patient and 25 control sera.

View original record on NIH RePORTER →